Phospho-PAK2 (S197) Antibody

What is PAK2 and what is the significance of S197 phosphorylation?

PAK2 (p21-activated kinase 2) is a serine/threonine kinase with a calculated molecular weight of approximately 58 kDa that plays critical roles in various cellular processes including cytoskeletal reorganization, cell motility, and signal transduction. The phosphorylation at serine 197 (S197) represents one of several key regulatory phosphorylation sites on PAK2, alongside S141, S192, and T402. This specific phosphorylation event is associated with the release of the auto-inhibitory domain, contributing to PAK2 activation. The S197 site has been identified as a target of multiple upstream kinases including AMPK, highlighting its importance in metabolic signaling networks .

How does PAK2 S197 phosphorylation differ from other PAK family phosphorylation events?

While the PAK family members (PAK1-6) share structural similarities, their phosphorylation patterns and regulatory mechanisms display distinct characteristics. For PAK2 specifically, phosphorylation at S197 occurs within a unique sequence context that allows for specific antibody recognition. Unlike some phosphorylation events that are common across PAK isoforms, antibodies targeting phospho-S197 of PAK2 show no cross-reactivity with other proteins, making this modification a suitable target for isoform-specific detection . This specificity is particularly important when studying PAK2 functions that are distinct from other PAK family members, especially in contexts where multiple PAK proteins are expressed simultaneously.

Which upstream kinases are known to phosphorylate PAK2 at S197?

Several kinases have been identified that directly phosphorylate PAK2 at the S197 position:

• AMP-activated protein kinase (AMPK), particularly AMPKα2, has been confirmed to phosphorylate S197 of PAK2 in vitro

• VRK2 (vaccinia-related kinase 2) has been shown to mediate PAK2 S197 phosphorylation downstream of PD-1 signaling in T cells

• β-arrestin-dependent signaling pathways have been associated with changes in PAK2 phosphorylation status, including at position T169, which may indirectly influence S197 phosphorylation

This multi-kinase regulation suggests that S197 phosphorylation serves as an integration point for diverse signaling pathways.

What are the validated applications for phospho-PAK2 (S197) antibodies in research?

According to manufacturer specifications and research publications, phospho-PAK2 (S197) antibodies have been validated for several experimental applications:

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative measurement of phosphorylated PAK2

• Immunohistochemistry (IHC): Successfully used on formalin/PFA-fixed paraffin-embedded tissue sections, particularly in human breast carcinoma samples

• Western blotting: For detecting endogenous levels of PAK2 only when phosphorylated at S197

The antibodies have demonstrated reactivity across human, mouse, and rat samples, making them versatile tools for comparative studies across species .

What are the recommended protocols for sample preparation when detecting phospho-PAK2 (S197)?

For optimal detection of phosphorylated PAK2 at S197, researchers should consider the following protocol recommendations:

• For cell lysates:

  • Harvest cells at appropriate time points following stimulation

  • Lyse cells in buffer containing phosphatase inhibitors (critical for preserving phosphorylation status)

  • Clear lysates by centrifugation before proceeding with immunoblotting or immunoprecipitation

• For tissue samples intended for IHC:

  • Fixation in 10% neutral buffered formalin

  • Paraffin embedding and sectioning at 4-6 μm thickness

  • Antigen retrieval (typically heat-induced in citrate buffer pH 6.0)

  • Blocking of endogenous peroxidase activity and non-specific binding

  • Incubation with primary antibody at dilutions between 1:50-1:100

• For phosphoproteomics:

  • SILAC labeling approach helps quantitatively assess changes in phosphorylation status

  • Immunoprecipitation using phospho-specific antibodies can enrich for phosphorylated proteins

How can I verify the specificity of phospho-PAK2 (S197) antibody signals in my experiments?

Verification of antibody specificity is crucial for reliable data interpretation. The following approaches are recommended:

• Blocking peptide competition: Preincubate the antibody with a synthetic phosphopeptide corresponding to the S197 region. This should abolish specific immunoreactivity, as demonstrated in immunohistochemical staining of human breast carcinoma tissue .

• Phosphatase treatment: Treating samples with lambda phosphatase prior to immunoblotting should eliminate signal if it genuinely represents phosphorylated protein.

• siRNA knockdown: Depleting PAK2 using siRNA should result in loss of the specific band/signal corresponding to phospho-PAK2.

• Mutagenesis controls: Expressing S197A mutant PAK2 should not be recognized by the phospho-specific antibody, confirming specificity for the phosphorylated residue .

• Stimulus-response validation: Treatments known to induce PAK2 phosphorylation (e.g., AMPK activation) should increase signal intensity, while inhibitors should reduce it .

How does PAK2 S197 phosphorylation contribute to β-arrestin-mediated signaling networks?

Global phosphoproteome analysis has revealed that PAK2 is a component of β-arrestin-mediated signaling networks. Specifically, phosphorylation of PAK2 at T169 was observed to increase 2.2-fold following SII stimulation of AT1aR (angiotensin II type 1a receptor) . While direct evidence for S197 phosphorylation in this context was not explicitly shown in the provided references, the involvement of PAK2 in this signaling pathway suggests potential coordinated regulation of multiple phosphorylation sites, including S197.

The β-arrestin-mediated phosphoproteome includes 288 phosphopeptides from 220 phosphoproteins, with PAK2 being among the proteins whose phosphorylation status increases upon stimulation. This positions PAK2 within a complex network of kinases and phosphatases that mediate β-arrestin-dependent cellular responses .

What is the relationship between VRK2, PAK2 S197 phosphorylation, and PD-1 signaling in T cells?

Recent research has uncovered a fascinating relationship between VRK2 (vaccinia-related kinase 2), PAK2 S197 phosphorylation, and immune checkpoint signaling:

• VRK2 has been identified as a mediator of PAK2 S197 phosphorylation downstream of PD-1 receptor engagement

• Knockdown of VRK2 significantly diminishes PD-1 inhibition of cytokine secretion in T cells

• PAK2 S197 phosphorylation appears to function as a downstream effector in the PD-1 signaling pathway

• Interestingly, PAK2 is also phosphorylated upon TCR activation, and VRK2 knockdown abrogates this TCR-induced PAK2 phosphorylation

This dual role in both PD-1 and TCR signaling suggests that PAK2 S197 phosphorylation may serve as an integration point for seemingly opposing pathways in T cell regulation . These findings have therapeutic implications, as VRK2 inhibition has been shown to synergize with PD-1 blockade to improve T cell-mediated anti-tumor responses.

How does AMPK regulate PAK2 through S197 phosphorylation?

Chemical genetic screening for AMPKα2 substrates has identified PAK2 as a direct target of AMPK. Specifically:

• Both S20 and S197 of PAK2 were phosphorylated in vitro by AMPK

• Mutation of serine 20 to alanine abolished the phosphorylation of PAK2 by AS-AMPKα2 in experimental systems

• The phosphorylation occurs within a specific sequence context surrounding S197

• This regulation links PAK2 activity to cellular energy sensing through the AMPK pathway

The identification of PAK2 as an AMPK substrate connects energy metabolism regulation to cytoskeletal dynamics and cell motility, potentially explaining how metabolic stress affects cellular migration and adhesion processes.

What are the common technical challenges in detecting phospho-PAK2 (S197) and how can they be addressed?

Researchers commonly encounter several challenges when working with phospho-specific antibodies against PAK2 S197:

• Low signal intensity: This can be addressed by:

  • Optimizing lysis conditions with fresh phosphatase inhibitors

  • Enrichment of phosphoproteins prior to detection

  • Using enhanced chemiluminescence detection systems

  • Considering the timing of stimulation, as phosphorylation events may be transient

• Background or non-specific signals: Minimize by:

  • Increasing blocking time or concentration of blocking agent

  • Optimizing antibody dilution (typically 1:50-1:100 for IHC applications)

  • Using phospho-blocking peptides as negative controls

  • Including proper negative controls (untreated samples, phosphatase-treated samples)

• Variability between experiments: Reduce by:

  • Standardizing cell culture conditions and passage number

  • Careful timing of stimulations and inhibitor treatments

  • Including proper loading controls and normalization procedures

  • Using quantitative methods like ELISA when possible

• Species cross-reactivity issues: While the antibodies are reported to work across human, mouse, and rat samples , optimization may be required when switching between species.

How should researchers interpret changes in PAK2 S197 phosphorylation in different experimental contexts?

Interpretation of PAK2 S197 phosphorylation data requires careful consideration of multiple factors:

What approaches can be used to study the functional consequences of PAK2 S197 phosphorylation?

To investigate the functional significance of PAK2 S197 phosphorylation, researchers can employ several complementary approaches:

• Phosphomimetic and phospho-deficient mutants:

  • S197A mutation prevents phosphorylation

  • S197D or S197E mutations mimic constitutive phosphorylation

  • Comparing the phenotypes of cells expressing these mutants can reveal the role of this modification

• Pharmacological manipulation:

  • AMPK activators (e.g., AICAR, metformin) to increase S197 phosphorylation

  • VRK2 inhibitors to decrease phosphorylation in T cell contexts

  • Compound A-769662 (direct AMPK activator) for more specific activation

• Cellular assays to assess downstream functions:

  • Cytoskeletal reorganization (F-actin staining)

  • Cell migration assays (wound healing, transwell)

  • Kinase activity assays using PAK2 substrates

  • T cell activation and cytokine production measurements when studying immune contexts

• Temporal correlation with biological outcomes:

  • Time-course experiments correlating S197 phosphorylation with cellular events

  • Live-cell imaging using fluorescent biosensors for PAK2 activity

• Genetic approaches:

  • CRISPR/Cas9-mediated genome editing to introduce S197A mutations at the endogenous locus

  • Conditional knockout systems to study PAK2 function in specific tissues or time points

How is phospho-PAK2 (S197) being utilized in cancer research?

Phospho-PAK2 (S197) antibodies have emerging applications in cancer research, particularly in:

• Breast cancer studies: Immunohistochemical staining of human breast carcinoma tissue has successfully employed phospho-PAK2 (S197) antibodies, suggesting potential diagnostic or prognostic applications .

• Leukemia/lymphoma research: PAK kinase inhibition has demonstrated therapeutic activity in preclinical models of adult T-cell leukemia/lymphoma. Specifically, phospho-Ser20-PAK2 has been correlated with the ability of cell lines to form tight aggregates in suspension culture, while PF treatment (PAK inhibitor) reduced PAK2 phosphorylation on both Ser20 and Ser141 residues .

• Therapeutic target identification: The connection between VRK2-mediated PAK2 S197 phosphorylation and PD-1 signaling suggests potential for combination therapies targeting both VRK2 and immune checkpoint pathways. Research indicates that VRK2 inhibition synergizes with PD-1 blockade to improve T cell-mediated anti-tumor responses .

What is known about the interplay between PAK2 S197 phosphorylation and other post-translational modifications?

The regulation of PAK2 involves a complex interplay between multiple phosphorylation sites and other post-translational modifications:

• Multiple phosphorylation sites: PAK2 activation is associated with auto-phosphorylation at multiple sites including S141, S192, S197, and T402, which collectively contribute to releasing the auto-inhibitory domain from the kinase domain .

• Hierarchical phosphorylation: Evidence suggests potential sequential phosphorylation, where modification at one site may influence the likelihood of phosphorylation at other sites.

• Cross-talk with other modifications: While not explicitly detailed in the provided references, research in related kinases suggests potential cross-talk between phosphorylation and other modifications such as acetylation, ubiquitination, or sumoylation.

• Stimulus-specific phosphorylation patterns: Different upstream activators (AMPK vs. VRK2) may induce distinct patterns of multi-site phosphorylation, leading to context-specific PAK2 functions .

Further research is needed to fully elucidate how S197 phosphorylation cooperates with other modifications to fine-tune PAK2 activity in different cellular contexts.